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Abstract
Many common diseases are highly polygenic, modulated by
a large number genetic factors with small effects on suscep-
tibility to disease. These small effects are difficult to map
reliably in genetic association studies. To address this prob-
lem, researchers have developed methods that aggregate in-
formation over sets of related genes, such as biological path-
ways, to identify gene sets that are enriched for genetic vari-
ants associated with disease. However, these methods fail to
answer a key question: which genes and genetic variants are
associated with disease risk? We develop a method based
on sparse multiple regression that simultaneously identifies
enriched pathways, and prioritizes the variants within these
pathways, to locate additional variants associated with dis-
ease susceptibility. A central feature of our approach is
an estimate of the strength of enrichment, which yields a
coherent way to prioritize variants in enriched pathways.
We illustrate the benefits of our approach in a genome-
wide association study of Crohn’s disease with ∼440,000
genetic variants genotyped for ∼4700 study subjects. We
obtain strong support for enrichment of IL-12, IL-23 and
other cytokine signaling pathways. Furthermore, prioritiz-
ing variants in these enriched pathways yields support for
additional disease-association variants, all of which have
been independently reported in other case-control studies
for Crohn’s disease.
Author Summary
Genome-wide association studies have helped locate genes
that contribute to common diseases. The analysis of these
studies is typically straightforward: systematically test each
genetic variation in isolation whether it is correlated with
susceptibility to disease. This approach often works well to
identify commonly occurring variants with moderate effects
on disease risk, but the effects of many variants are so small
they fail to show statistically significant correlations. This
is a concern because many common diseases are modulated
by a large number of genetic factors with small effects on
disease risk. An alternative strategy is to examine groups
of variants, such as variants sharing a common biological
pathway, and to test whether each group is enriched for
disease correlations. This can be a more effective approach
to identify genetic factors relevant to disease. However, it
does not indicate which individual genes or variants are
associated with disease, which remains an important ques-
tion. To address this limitation, we describe a statistical
framework that integrates enrichment analysis with disease-
correlation tests for variants. We illustrate this approach in
a case-control study for Crohn’s disease. We show that our
approach uncovers disease-susceptibility genes that are not
identified in conventional analyses of the same data.
Introduction
By surveying genetic variation throughout the genome, and
systematically searching for variants correlated with disease
phenotypes, genome-wide association studies (GWAS) have
led to the discovery of genes and genetic loci that were not
previously suspected of playing a role in complex diseases
[1–4]. For example, the discovery of disease-correlated vari-
ants in GWAS of Crohn’s disease, a common form of inflam-
matory bowel disease, has helped draw links to genes that
regulate autophagy and innate immune responses [5–10].
In most analyses of GWAS, genetic associations are
identified by testing each marker one at a time for asso-
ciation with disease. Additional clues about genetic vari-
ants, such as whether they are coding, exonic, or lie near
the transcription start site of a gene, are usually consid-
ered post hoc, rather than incorporated into the statistical
analysis. While such “hypothesis-free” analyses have suc-
cessfully identified variants associated with disease, they
have important shortcomings. Many commonly occurring
diseases are believed to be modulated by a large number
of genetic factors, each which have a small effect on dis-
ease risk, so they may be difficult to identify in a GWAS
[11–14]. This problem is compounded, according to some
predictions [11, 12, 15, 16], by the low prevalence of many
alleles conferring risk to complex diseases. Motivated by
these shortcomings, researchers have developed “pathway
analysis” approaches to GWAS [17–21]. These methods are
grounded on the theory that complex disease arises from the
accumulation of genetic effects acting within common bio-
logical pathways [22–25]. A main goal of pathway analysis
is to identify pathways that are enriched for disease—that
is, groups of related genes that are more likely to harbour
disease-associated variants compared to arbitrary regions
of the genome. Pathway analysis can improve power to un-
cover genetic factors relevant to disease because identifying
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the accumulation of small genetic effects acting in a com-
mon pathway is often easier than mapping the individual
genes within the pathway that contribute to disease sus-
ceptibility.
A limitation of analyses that identify enriched path-
ways is that they do not provide feedback about associated
variants within these pathways; identifying an enriched set
of genes does not indicate which variants are associated
with the disease, or even which genes harbour such vari-
ants. Yet discovery of associated variants and genes is a
primary motivation for GWAS, and an important step to-
ward understanding the biology of disease and, ultimately,
developing effective medical therapies. In principle, iden-
tifying enriched pathways should help us locate variants
associated with disease, because knowing that a variant
lies in or near a gene in an enriched pathway makes it a
better disease-association candidate. Therefore, prioritiz-
ing these variants—say, by slightly relaxing thresholds of
significance—should yield a greater number of reproducible
associations for a given rate of false positives. But it is un-
clear how to implement this in practice: to what extent can
we relax significance thresholds while keeping the rate of
false positives at an acceptable level?
To address this problem, we develop a model-based ap-
proach for joint analysis of pathways and genetic variants,
in which we interpret enrichment as a model parameter.
The enrichment parameter quantifies the increase in the
probability that each variant in the pathway is associated
with disease risk. By jointly analyzing variants and path-
ways, our method adjusts association evidence in light of
estimated pathway enrichments—sometimes called pathway
or gene prioritization [22, 26–34]—and, simultaneously, ad-
justs enrichment estimates to reflect evidence of associa-
tions in pathways.
Our approach builds on statistical methods for simulta-
neous mapping of genetic variants in GWAS [35–43]. In con-
trast to single-marker regression approaches, these meth-
ods model susceptibility to disease by the combined effect
of multiple variants, and use sparse multivariate regression
techniques to fit multi-marker (i.e. polygenic) models to the
data. By adopting a multi-marker disease model, estimat-
ing enrichment effectively reduces to counting, inside and
outside each candidate pathway, variants associated with
disease—more precisely, the variants that are included in
the polygenic disease model. Our approach to combining
multi-marker modeling with pathway analysis offers sev-
eral benefits. First, compared to single-marker approaches,
multi-marker modeling improves power to detect genetic as-
sociations [37, 41, 44]. Second, unlike many pathway anal-
ysis methods that test for enrichment of significant SNPs
or genes in a pathway [20], we have no need to select a
significance threshold for p-values; instead, we use the as-
sociation signal across all genes to assess enrichment. Third,
by analyzing variants simultaneously, we avoid exaggerat-
ing evidence for enrichment from associated variants that
are correlated with each other (i.e. in linkage disequilib-
rium), while still allowing multiple independent association
signals near a gene to contribute evidence for enrichment.
And fourth, quantifying enrichment within this framework
naturally gives us feedback about associations within en-
riched pathways, potentially leading to discovery of novel
genetic loci underlying disease.
Though we focus on incorporating pathways (and,
more broadly, biologically related gene sets) into analy-
sis of GWAS, our methods also apply to other types of
genome annotations. In this respect, our work is related to
other model-based approaches for estimating enrichment of
genome-wide association signals across functionally related
genomic regions, like transcription factor binding sites [45–
48]. One distinguishing feature of our approach is that we
have the ability to test for enrichment, which is important
for assessing which candidate pathways show the strongest
support for enrichment. We assess support for enrichment
by framing it is as a model comparison problem. An advan-
tage of this approach is that we can use the same approach
to assess support for the enrichment of combinations of two
or more pathways. This is useful, for example, if a pathway
relevant to disease pathogenesis is ranked highly only after
combining it with another pathway relevant to the disease.
Another feature that distinguishes our analysis is that
we use multiple pathway databases in an attempt to inter-
rogate pathways as comprehensively as possible—the more
pathways we consider, the greater chance we have of draw-
ing new connections between pathways, genes within these
pathways, and complex disease. We demonstrate how us-
ing our approach to comprehensively interrogate pathways
results in increased evidence for enrichment, and is robust
to inclusion of a large number of irrelevant pathways. Our
study includes ∼3100 candidate pathways drawn from eight
well-developed pathway databases available on the Web
[33, 49, 50].
We demonstrate our approach in a detailed analysis of
a GWAS for Crohn’s disease with about 440, 000 single nu-
cleotide polymorphisms (SNPs) genotyped in roughly 1700
cases and 3000 controls. This is a convenient study for
gauging the benefits of our approach because genetic as-
sociations have already been published based on data from
this study [51], and pathway analyses of these data have
found evidence for enriched pathways [17, 52–55]. Our en-
richment results highlight the role of cytokines that mod-
ulate immune responses in Crohn’s disease, and the IL-12
and IL-23 signaling pathways, which have been previously
linked to the disease [8, 55, 56]. And, by prioritizing vari-
ants within these enriched pathways, our method identifies
disease-susceptibility candidates that are not deemed sig-
nificant in conventional analyses of the same data, including
the STAT3 gene, the IBD5 locus, and the major histocom-
patibility complex (MHC) class II genes. All these genetic
associations have been independently confirmed in other
studies, demonstrating that our methods have the poten-
tial to yield novel biological insights.
Overview of statistical analysis
Our approach builds on previous work that casts simul-
taneous analysis of genetic variants as a variable selection
problem—the problem of deciding which variables (the ge-
netic variants) to include in a multivariate regression of
the phenotype. We begin with a method that assumes each
variant is equally likely to be associated with the pheno-
type [36, 37], then we modify this assumption to allow for
enrichment of associated variants in a pathway.
The data from the GWAS are the genotypes X =
(x1, . . . , xn)
T and phenotypes y = (y1, . . . , yn)
T from n
study participants. Here we assume the genetic markers
are SNPs, and the phenotype is disease status: patients with
the disease (“cases”) are labeled yi = 1, and disease-free in-
dividuals (“controls”) are labeled yi = 0. Entries of the n×p
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matrix X are observed minor allele counts xij ∈ {0, 1, 2},
or expectations of these counts estimated using genotype
imputation [57, 58], for each of the n samples and p SNPs.
We assume an additive model of disease risk, in which
the log-odds for disease is a linear combination of the minor
allele counts:
log
{
p(yi = 1)
p(yi = 0)
}
= β0 + xi1β1 + · · ·+ xipβp. (1)
Under this additive model, eβj is the odds ratio, the mul-
tiplicative increase in odds of disease for each copy of the
minor allele at locus j. We do not consider dominant or
recessive effects on disease risk, but it would be straightfor-
ward to include them; see [59]. This method is also easily
adapted to quantitative traits by replacing (1) with a linear
regression for y.
Although the log-odds for disease is expressed in (1) as
a linear combination of all SNPs, we assume most SNPs j
have no effect on disease risk (βj = 0). We refer to SNPs j
that have non-zero coefficients (βj 6= 0) as being “included”
in the multi-marker disease model. A SNP’s inclusion sig-
nals that it affects susceptibility to disease, or that is in
linkage disequilibrium with other, possibly untyped, risk-
conferring variants. Therefore, the main goal of the analy-
sis is to compute, for each SNP j, the posterior inclusion
probability, PIP(j) ≡ p(βj 6= 0 |X, y). A high posterior in-
clusion probability is the analogue of a small p-value in a
conventional single-marker analysis.
To obtain these posterior inclusion probabilities, we
must first specify a prior. A standard assumption, and the
assumption made in previous approaches [36, 37], is that
SNPs are equally likely to be associated with the pheno-
type a priori; that is, pij ≡ p(βj 6= 0) is the same for all
SNPs.
To model enrichment of associations within a pathway,
we modify this prior. Precisely, the prior inclusion proba-
bility for SNP j depends on whether or not it is assigned
to the enriched pathway:
log10
(
pij
1− pij
)
= θ0 + ajθ. (2)
The pathway indicators aj keep track of which SNPs are
assigned to the enriched pathway: aj = 1 when SNP j is as-
signed to the enriched pathway, otherwise aj = 0. (In brief,
a SNP is assigned to a pathway if it is near a gene in the
pathway; see Methods.) We refer to θ0 as the genome-wide
log-odds, since it reflects the overall proportion of SNPs
that are included in the multi-marker disease model. (More
precisely, it is the proportion for SNPs not assigned to the
pathway, but this is usually most SNPs.) We refer to θ as
the enrichment parameter because it corresponds to the in-
crease in probability (on the log-odds scale) that a SNP
assigned to the pathway is included in the model. For ex-
ample, θ0 = −5 and θ = 2 indicates that 1 out of every
10,000 SNPs outside the pathway is included in the multi-
marker model, but for SNPs assigned to the pathway, 1
out of every 100 are included. If θ = 0, this reduces to the
standard prior assumption made by previous methods. We
expect θ to be zero, or close to zero, for most pathways.
To assess evidence for enrichment of a candidate path-
way with indicators a = (a1, . . . , ap), we compute a Bayes
factor [60, 61]:
BF(a) =
p(y |X, a, θ > 0)
p(y |X, θ = 0) . (3)
This Bayes factor (BF) is the ratio of likelihoods under
two models, the model in which the candidate pathway is
enriched for SNPs included in the multi-marker regression
(θ > 0), and the null model that no pathways are enriched
(θ = 0). A larger BF implies stronger evidence for enrich-
ment. We compute each BF by averaging, or integrating,
over the unknown parameters, and over multi-marker mod-
els with different combinations of SNPs, using appropriate
prior distributions for θ0 and θ (see Methods).
We use the same approach to test for joint enrichment
of multiple candidate pathways. We compute BF(a) as be-
fore (eq. 3), except that we set aj to 1 whenever SNP j
is assigned to at least one of the pathways. In this case, θ
represents the increased rate of associations among SNPs
assigned to one or more of the pathways. This is equivalent
to assuming that all enriched pathways have the same level
of enrichment. It would be possible to relax this assump-
tion, but at the cost of complicating the analysis, so we
restrict ourselves to a single enrichment parameter.
To assess evidence for association of individual variants
with the phenotype, we compute PIP(j) for each variant
j. These posterior probabilities depend on which pathways
are enriched, and on the strength of enrichment θ, because
these factors affect the prior probabilities pij , which in turn
affect the posterior probabilities PIP(j) following Bayes’
rule. (In practice, we account for uncertainty in θ0 and
θ when calculating the posterior probabilities by averag-
ing over θ0 and θ; see Methods.) Since enrichment leads
to higher prior inclusion probabilities for SNPs in the en-
riched pathway, an association that is not identified by a
conventional genome-wide analysis, perhaps because the al-
lele appears infrequently in the population, or because the
nearby functional polymorphism has only a small effect on
disease risk, may become a strong candidate in light of its
presence in an enriched pathway. Because we estimate θ
from the data, the extent to which we prioritize variants
in enriched pathways is determined by the data. In this
way, our framework integrates the problem of identifying
enriched pathways with the problem of prioritizing variants
within enriched pathways.
Results
We illustrate our methods through an extended example—
analysis of genome-wide marker data from the WTCCC
Crohn’s disease study [51]. After steps to ensure data qual-
ity, the data consist of ∼440, 000 SNPs genotyped for 1748
cases and 2938 controls. (See Methods for details.) Crohn’s
disease is well suited to illustrating the benefits of path-
way analysis because many pathways related to immune
function and inflammatory response have been character-
ized. Additionally, genetic associations have been published
based on data from this study [51], and have been repli-
cated in a follow-up study [62]. Beyond these association
analyses, enrichment analyses of these data have provided
further support for links between Crohn’s disease and path-
ways related to adaptive and innate immunity [17, 52–55].
We have three main goals in presenting this case study:
first, to explain how to use and interpret the BFs, PIPs,
and other statistics relevant to joint analysis of variants
and pathways; second, to highlight the features, and limita-
tions, of our approach; and third, to examine the hypothesis
that we can gain additional insights into Crohn’s disease by
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reassessing the evidence for associations between variants
and disease in light of pathway enrichment findings.
Our analysis proceeds in three stages. First, we compute
a BF for each candidate pathway, and use these Bayes fac-
tors to rank the pathways. Second, based on this ranking,
we assess evidence for models in which two or more path-
ways are enriched. Third, we investigate whether the most
compelling pathway enrichments can help us locate Crohn’s
disease associations beyond those identified in analyses that
ignore information about pathways.
Bayes factors for enriched pathways
To rank the 3158 candidate pathways by their evidence for
enrichment, we compute, for each pathway, a Bayes Factor
that measures support for enrichment relative to the null
hypothesis. All candidate pathways have been curated by
domain experts, or are based on experimental evidence in
other organisms and inferred via gene homology. To be as
comprehensive as possible, we draw pathways from a va-
riety of publicly accessible collections, and we include all
pathways, even those that are unlikely to be relevant to
Crohn’s disease based on current understanding of disease
pathogenesis. To help make our results replicable, we doc-
ument the pathway databases used, and the steps taken to
compile gene sets from these pathway data. (See Table 4
for the list of pathway databases used; see Supplementary
Results for statistics on gene sets and gene coverage from
these databases; see Methods for retrieval and processing
of pathway data, and assignment of SNPs to pathways.)
Many of the pathways in the databases are arranged
hierarchically—we include all elements of the hierarchy in
our analysis. Elements in upper levels of the hierarchy refer
to groups of pathways with shared attributes or a common
function. Some groups have a broad definition, such as “im-
mune system” in Reactome, which includes pathways in-
volved in adaptive and innate immune response. (Hereafter,
we use the term “pathway” to refer to a set of biologically
related genes.) Enrichment of a broad group of genes is
unlikely to provide novel insights into disease pathogene-
sis. However, a key step in our analysis is to re-interrogate
SNPs for association in light of inferred enrichments. Thus,
enrichment of a broad physiological target like “immune
system” can be useful if subsequent re-interrogation reveals
associations that were not significant in a conventional anal-
ysis.
We find that the vast majority of pathways show lit-
tle or no evidence for enrichment; of the 3518 candidate
pathways, 2850 (90%) have BF < 1, and an additional 233
pathways (7%) have BFs between 1 and 10. Table 1 shows
the 18 pathways with BF > 100. The cutoff at 100, as with
any cutoff, is somewhat arbitrary. We discuss this issue and
interpretation of the BFs below.
Several gene sets in Table 1 are subsets of one another
(refer to Fig. B.1 for relationships among these pathways
in the Reactome and PID hierarchies). For example, “im-
mune system” overlaps with eight other pathways in the
table, including cytokine signaling. Several pathways ap-
pear in the table twice because the NCBI BioSystems and
Pathway Commons databases sometimes disagree about
the set of genes assigned to a pathway. These discrepancies
can have a substantial impact on the results. For example,
the BF for the Pathway Commons version of cytokine sig-
naling is smaller than the BioSystems version by a factor of
roughly 1000, due primarily to the lack of inclusion of NOD2
and MHC genes that contribute to the association signal.
Conversely, the BF for the Pathway Commons version of IL-
23 signaling is about 80 times larger than the BioSystems
version because the former includes the NF-κB pathway,
and this pathway contains several genes that contribute
to the associational signal, notably NOD2. (Inclusion of
the NF-κB pathway is supported by experimental evidence
[67].) These results illustrate the benefits of a comprehen-
sive analysis that considers pathways from multiple sources.
Also note that no pathways from HumanCyc and KEGG,
which are mainly focused on metabolic pathways, show up
in Table 1 (nor do any pathways from Cancer Cell Map,
PANTHER and WikiPathways). This points to the robust-
ness of our approach to inclusion of a large number of ir-
relevant pathways.
All the pathways in Table 1 are related in some way
to immune system function. These pathways implicate
key actors in responses to pro-inflammatory stimuli and
in regulation of innate and adaptive immunity. This in-
cludes members of the NF-κB/Rel family, T-cell receptors
(TCRs), members of the protein tyrosine phosphatase fam-
ily (PTPs), mitogen-activated protein (MAP) kinases such
as c-Jun NH2-terminal kinases (JNKs), and chemokine re-
ceptors (CXCRs) [68–71].
In this initial ranking, three pathways stand out as hav-
ing stronger evidence for enrichment than the others: cy-
tokine signaling in immune system, IL23-mediated signal-
ing events, and IL12-mediated signaling events. The “cy-
tokine signaling in immune system” pathway, with BF =
7.9 × 105, is a collection of cytokine-driven networks that
modulate immune responses. Cytokines, a class of chemical
messengers that includes interferons (IFNs), interleukins
(ILs) and tumor necrosis factors (TNFs), have well under-
stood roles in immune processes. Accordingly, they exhibit
a complex relationship to autoimmunity: in addition to pro-
moting inflammatory and immune responses, they play an
important role in suppressing immunity [72]. Accumulating
evidence points to cytokines, and the signaling cascades
initiated by these cytokines, in a range of autoimmune dis-
orders, including inflammatory bowel disease [9, 73, 74].
Enrichment of “cytokine signaling in immune system” is
consistent with this view. Even though it implicates a broad
class of genes (the BioSystems version has 225 genes), en-
richment for Crohn’s disease associations is biologically
plausible; immune response involves a complex interplay
among signaling pathways, so a collection of pathways may
explain the pattern of genetic associations better than any
single signal transduction pathway.
Enrichment of the IL-23 pathway for Crohn’s disease
associations is consistent with its involvement in intesti-
nal inflammation, specifically in mediating differentiation of
CD4+ Th17 cells [75]. Additional findings from mouse mod-
els and genetic association studies support its role in inflam-
matory bowel disease [9, 56, 75–77]. IL-12 is also thought
to be important for immune response and differentiation of
Th17 cells, even if many of the regulating activities previ-
ously ascribed to IL-12 are due to IL-23 instead [10, 75].
Although IL-12 and IL-23 have distinct functions in regu-
lation of T helper cells, their pathways have many cytokine
and cytokine receptor components in common [78], so it
may be difficult to tease apart their roles in disease solely
by looking at enrichment in their gene sets; of the 66 genes
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Table 1. Pathways, and groups of related pathways, that exhibit the strongest evidence for enrichment
of Crohn’s disease associations, as measured by their Bayes factors
number of Bayes
enriched pathway database genes/SNPs factor θ¯0 enrichment θ¯
Cytokine signaling in immune system React. (BS) 225/6711 7.9×105 −4.1 1.96 (1.25–2.50)
IL23-mediated signaling events PID (PC) 66/2218 9.1×103 −3.9 2.01 (1.50–2.50)
IL12-mediated signaling events PID (PC) 111/3641 5.4×103 −4.0 1.90 (1.25–2.50)
Immune system React. (BS) 755/20,959 1.3×103 −4.1 1.44 (0.75–2.00)
Signaling by interleukins React. (BS) 111/3678 769 −3.9 1.70 (1.25–2.25)
Interferon gamma signaling React. (BS) 73/2290 700 −3.8 1.73 (1.25–2.25)
Immune system React. (PC) 529/15,074 692 −4.1 1.49 (0.75–2.00)
Interferon signaling React. (BS) 111/2965 491 −3.8 1.68 (1.25–2.25)
Cytokine signaling in immune system React. (PC) 193/6194 292 −3.9 1.55 (1.00–2.25)
Signaling events mediated by TC-PTP PID (PC) 92/3044 219 −3.9 1.62 (1.00–2.25)
TAK1 activates NF-κB by phosphory-
lation and activation of IKKs complex
React. (BS) 24/844 181 −3.8 2.00 (1.25–2.50)
Selective expression of chemokine
receptors during T-cell polarization
BioCarta 29/880 139 −3.8 2.01 (1.25–2.75)
IL27-mediated signaling events PID (PC, BS) 26/796 130 −3.8 2.00 (1.25–2.50)
IL23-mediated signaling events PID (BS) 37/1252 119 −3.8 1.89 (1.25–2.50)
CXCR4-mediated signaling events PID (PC) 190/6733 118 −3.9 1.43 (0.75–2.00)
Activated TAK1 mediates p38 MAPK
activation
React. (BS) 17/535 116 −3.8 2.07 (1.25–2.75)
TCR signaling in na¨ıve CD4+ T cells PID (PC) 133/4809 103 −3.9 1.47 (0.75–2.00)
JNK phosphorylation and activation
mediated by activated human TAK1
React. (BS) 16/559 102 −3.8 2.03 (1.25–2.75)
The table includes all gene sets with BF > 100. Abbreviations used in this table: React. = Reactome [63], PID = NCI Nature
Pathway Interaction Database [64], BS = NCBI BioSystems [65], PC = Pathway Commons [66]; θ¯0 = posterior mean of
genome-wide log-odds θ0 given that pathway is enriched; θ¯ = posterior mean of enrichment θ (and 95% credible interval) given
that pathway is enriched. The credible interval is the smallest interval about the posterior mean that contains θ with 95%
posterior probability. It is calculated to the nearest 0.25 using a numerical approximation (see Supplementary Methods). Note
that these numbers may not be reproduced exactly in an independent analysis using the same method, due to stochasticity in our
approximate computations. However, only slight deviations from these numbers are expected.
assigned to the IL-23 pathway, 54 are assigned to the IL-12
pathway (Pathway Commons version).
Previous findings from genome-wide association stud-
ies have linked autophagy genes ATG16L1 and IRGM to
Crohn’s disease [51, 79, 80]. Our pathway analysis does not
provide additional support for autophagy in Crohn’s disease
because pathways reflecting current models of autophagy
[9, 81] have not yet been incorporated, to our knowledge,
into any of the publicly available pathway databases.
Many of the pathways listed in Table 1 are related to
those identified in previous pathway analyses of Crohn’s
disease [17, 52–54], including Jak-STAT signaling [53] and
T cell receptor signaling [55]. Other pathways highlighted
in previous analyses show some evidence for enrichment in
our analysis, but these are eclipsed by much stronger enrich-
ment signals (Table 1). For example, Wang et al [55] obtain
the most evidence for enrichment of “IL12 and Stat4 depen-
dent signaling in Th1 development” (p-value = 8 × 10−5,
FDR = 0.045) based on enrichment analysis of BioCarta,
KEGG and Gene Ontology [82] gene sets, whereas this
pathway showed only modest evidence for enrichment in our
analysis (BF = 18) compared to the pathways in Table 1.
(Below, we obtain greater support for enrichment of this
pathway when combined with cytokine signaling genes.)
Moveover, all except one of the pathways in Table 1 are
from databases that were not included in [55]. These re-
sults illustrate the benefits of a comprehensive search for
enrichment across multiple pathway databases.
Given that enrichment analyses typically proceed by
computing p-values and assessing “significance,” one may
reasonably ask whether the BFs in Table 1 represent “sig-
nificant” evidence for enrichment. Specifying an appropri-
ate threshold for a BF to be considered significant, how-
ever, is context-dependent, and subjective. This is because
the posterior odds for a pathway being enriched, relative to
the null hypothesis that no pathways are enriched, is equal
to the Bayes Factor times the prior odds for enrichment,
and the prior odds for each pathway depends on how plau-
sible it is, a priori, that the pathway is involved in Crohn’s
disease pathogenesis. (Similar issues arise when specifying
significance thresholds for p-values. For example, the false
discovery rate at a given p-value threshold depends on the
prior probability of enrichment [83, 84]. In practice, how-
ever, significance thresholds of 0.05 or 0.01 are often used
without attending to this concern.) Nonetheless, we can
make the following observations. First, if we are willing to
assume the pathways in Table 1 are all equally plausible
candidates for enrichment a priori, then the ratio of the
BFs indicates the relative support for the enrichment hy-
potheses. For example, if we are forced to choose between
enrichment of “cytokine signaling in immune system” and
“IL23-mediated signaling events,” the data overwhelmingly
favour the former by a factor of 7.9×10
5
9.1×103 ≈ 87. Second, even
under a “conservative” prior for enrichment in which we
expect one pathway to be enriched among the 3158 can-
didates, corresponding to a prior odds of 1/3158, the top
5
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Table 2. Pairs of pathways with strongest evidence for joint enrichment of Crohn’s disease associations
number of Bayes
enriched pathways database genes/SNPs factor θ¯
cytokine signaling in immune system and . . .
IL23-mediated signaling events PID (BS) 247/7438 5.5×108 2.33
Selective expression of chemokine receptors during
T-cell polarization
BioCarta 248/7375 4.8×108 2.33
Th1/Th2 differentiation BioCarta 236/7090 3.6×108 2.32
NO2-dependent IL-12 pathway in NK cells BioCarta 239/7143 3.2×10
8 2.31
IL27-mediated signaling events PID (PC, BS) 238/7073 3.0×108 2.30
IL12-mediated signaling events PID (BS) 263/7807 2.4×108 2.30
IL-12 and Stat4 dependent signaling pathway in Th1
development
BioCarta 241/7272 2.4×108 2.30
IL23-mediated signaling events PID (PC) 266/8060 2.2×108 2.29
This table includes every model with two enriched pathways that has a BFs greater than 108. All these combinations includes
“cytokine signaling in immune system” (the Biosystems version with 225 genes). Refer to Table 1 for the legend. “Number of
genes/SNPs” gives the total number assigned to the enriched pathways. For every enrichment hypothesis listed in the table,
θ¯0 = 4.4, and the 95% credible interval for θ to the nearest 0.25 is (1.75–2.75). Refer to Fig. B.1 for relationships among
pathways in the Reactome and PID hierarchies.
three pathways have BFs that are large enough (greater
than 3158) to support enrichment.
Assessing combinations of pathways for enrichment
The initial ranking (Table 1) suggests that enrichment of
a group of pathways, cytokine signaling in immune sys-
tem, offers a better fit to the pattern of Crohn’s disease
associations than any one pathway. But the question re-
mains whether some other combination of pathways offers
a better fit. A benefit of our approach is that we can di-
rectly compare support for enrichment of different com-
binations of pathways by comparing their BFs (assuming
the same prior for these hypotheses). This is because the
ratio BF(a)/BF(a∗) is the same as the Bayes factor that
compares support for the enrichment model encoded by a
versus the model encoded by a∗. (By contrast, it is harder
to make such comparisons using p-values. For example, if p
is the p-value for testing hypothesis a against the null, and
p∗ is the p-value for testing a∗ against the null, it is not
clear how to compare support for a and a∗.)
We begin by computing BFs to quantify support for
enrichment of pairs of pathways. Since it is impractical to
consider all pairs, we tackle this in a “greedy” fashion by se-
lecting combinations of pathways based on the initial rank-
ing. Our strategy is to select pathways with the largest BFs
(here we take IL-23, IL-12 and cytokine signaling), and we
consider each of these in combination with pathways from
a larger set of candidates (here we use the 72 pathways
with BF > 10). This greedy heuristic makes it feasible to
evaluate many combinations of pathways that could plau-
sibly be jointly enriched, though since it does not consider
all combinations, there is the risk of overlooking a combina-
tion that provides a better fit to the pattern of associations.
In total, we compute BFs for 219 pairs of pathways, which
includes 3 combinations of IL-23, IL-12 and cytokine sig-
naling, and 216 = 3 × 72 combinations of IL-23, IL-12 or
cytokine signaling with another pathway.
Table 2 lists all models with two enriched pathways that
have BF > 108. As before, all these pathways are related
to innate and adaptive immune processes. Three of the
BioCarta pathways appearing in this table, including the
IL-12 and Stat4 dependent signaling pathway highlighted
in the enrichment analysis of [55], did not originally show
up in Table 1 because their BFs were less than 100. The
largest BF, for enrichment of IL-23 and cytokine signal-
ing, is unsurprising in light of the initial ranking, except
that this version of the IL-23 pathway does not include the
NF-κB pathway, which suggests that the NF-κB pathway
does not contribute additional evidence for enrichment once
we account for enrichment of cytokine signaling genes (14
of the 35 genes in the NF-κB pathway, including NOD2,
are also members of cytokine signaling). Among hypothe-
ses that do not involve cytokine signaling, the largest BF is
5.1×107, corresponding to a model in which IL-23 signaling
and interferon gamma signaling are enriched.
The top BF in Table 2 is ∼700 times greater than the
largest BF in Table 1. This suggests that the best model
with two enriched pathways provides a much better fit to
the data than the best model with any one enriched path-
way. However, to properly interpret this result we must
weigh this increase in the BF against the relative prior
plausibility of the models, which is difficult to quantify. A
naive argument using a “conservative” prior for any pair
of pathways being enriched might suggest a prior odds of
(1/3158)2, based on the conservative prior for a single path-
way we discussed above. This prior would make a 700-fold
increase in the BF appear to be relatively insignificant.
However, this argument not only depends on the earlier
prior, which may be overly conservative, but also assumes
independence of enriched pathways, which seems unwise
considering that many pathways mentioned here have re-
lated roles in immunity; a priori, one might expect that a
pathway is more likely to be enriched when a biologically
related pathway is enriched. With this in mind, we inter-
pret Table 2 as providing substantial, if short of compelling,
support for the hypothesis that two pathways are enriched
for Crohn’s disease associations. Perhaps a more important
question is whether these findings lead to identification of
additional loci affecting susceptibility to Crohn’s disease, a
question we address in the next section.
For completeness, we extend the analysis to models with
three enriched pathways. Again, following a greedy strat-
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Fig. 1. Scatterplots showing P1, the posterior probability that each genomic segment contains Crohn’s
disease associations, given different hypotheses about enriched pathways. Each point corresponds to a
segment of the genome containing 50 SNPs. Some of the segments are labeled by representative candidate genes. In
panel A, genes assigned to “cytokine signaling in immune system” are written in bold.
egy, we take all pairs of pathways with BF > 108 (Table 2)
and combine these pairs with individual pathways that have
BF > 100 (Table 1). Of the 126 resulting BFs, the largest
is 8.4× 109, corresponding to enrichment of IL-23 signaling
(Pathway Commons), cytokine signaling (BioSystems) and
“TAK1 activates NF-κB by phosphorylation and activation
of IKKs.” This BF is only about 3 times greater than the
largest BF in Table 2. Following our earlier arguments, this
result does not constitute strong support for enrichment of
three pathways.
Associations informed by enriched pathways
Now we examine how the pathway enrichment findings can
help us identify additional genetic associations. The intu-
ition is that, having established that variants near genes in
a pathway are more likely to be associated with the phe-
notype, it is reasonable to up-weight, or prioritize, these
SNPs in the statistical analysis. Our model-based frame-
work achieves this by estimating an enrichment parameter
representing the increased prior probability that SNPs as-
signed to the pathway are associated with the phenotype.
This prior probability in turn raises the posterior probabil-
ity of association for these SNPs. This ability to reassess
the evidence for association of individual loci in light of
enriched pathways is an important feature of our model-
based approach to pathway analysis, as identifying individ-
ual disease-susceptibility loci is potentially more informa-
tive than observing that a pathway is enriched for disease
associations. This is particularly the case for broad path-
ways, such as cytokine signaling in immune system, which
contains 225 genes, as only a small proportion of these genes
may actually harbour genetic variants that affect Crohn’s
disease risk.
In simultaneous analysis of genetic variants based on
Bayesian variable selection, it is preferable, at least ini-
tially, to assess evidence for associations across genomic
regions, rather than for individual SNPs. This is because
when SNPs are correlated with one another the association
signal can be spread across these SNPs, diluting the signal
at any given SNP [37]. Therefore, we divide the genome
into overlapping segments of 50 SNPs, with an overlap of
25 SNPs between neighbouring segments. For each segment,
we compute P1, the posterior probability that at least one
SNP in the segment is included in the multi-marker disease
model. We use segments with an equal number of SNPs so
that, under the null hypothesis of no enrichment, the prior
probability that at least one SNP is included is the same
for every segment. Since a segment spans, on average, 307
kb of the genome (98% of segments are between 100 kb and
1 Mb long), calculating P1 for these segments provides only
a low-resolution map of genetic risk factors for Crohn’s dis-
ease. Still, this resolution suffices for the objectives of this
case study. In other applications, one could increase the
resolution by calculating PIPs for individual SNPs within
selected regions. Hereafter, we use Pn to denote the poste-
rior probability that at least n SNPs are included.
First, we compare Crohn’s disease associations identi-
fied under the null hypothesis that no pathways are en-
riched with associations identified under the model in which
a single pathway, cytokine signaling in immune system, is
enriched. Figure 1A shows how the evidence for association
in each segment (P1) changes once we account for enrich-
ment of cytokine signaling genes. As expected, many seg-
ments (corresponding to points above the diagonal in the
scatterplot) show increased evidence for association under
the model in which cytokine signaling is enriched. These
segments contain SNPs assigned to the enriched pathway.
Segments corresponding to points on the diagonal show no
change in support for association, and these are segments
that do not contain SNPs assigned to the enriched pathway.
Although it is not clear from the figure due to over-plotting,
most segments lie near the bottom-left corner; when cy-
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Table 3. Selected regions of the genome with strong evidence for Crohn’s disease risk factors given that
two pathways are enriched for Crohn’s disease associations
critical
P1 P2 candidate
MAF
chr. region (Mb) null alt. null alt. gene(s) SNP ctrls cases
1p31 67.30–67.48 1.00 1.00 0.06 0.48 IL23R rs11805303 0.318 0.392
2q37 233.92–234.27 1.00 1.00 0.01 0.22 ATG16L1 rs10210302 0.481 0.402
5p13 40.32–40.66 1.00 1.00 0.42 0.42 PTGER4 rs17234657 0.124 0.181
∗ 5q23 129.54–132.04 0.18 0.86 0.02 0.29 multiple (IBD5) rs274552 0.166 0.128
∗ 6p21 32.3–32.92 0.49 0.98 0.02 0.31 MHC class II rs9469220 0.519 0.466
10q21 64.0–64.43 0.96 0.96 0.03 0.03 ZNF365 rs10995271 0.386 0.440
10q24 101.26–101.32 0.95 0.95 0.01 0.04 NKX2-3 rs7095491 0.470 0.528
16q12 49.0–49.4 1.00 1.00 0.11 0.77 NOD2 rs17221417 0.287 0.356
∗ 17q21 37.5–38.3 0.12 0.87 0.01 0.21 STAT3 rs744166 0.439 0.392
18p11 12.76–12.91 0.94 1.00 0.01 0.20 PTPN2 rs2542151 0.163 0.209
For every region in this table, there is at least a 0.8 probability that one or more SNPs in the region are included in the
multi-marker disease model (P1 ≥ 0.8) given the hypothesis that two pathways are enriched. Rows marked with an asterisk (∗)
are selected only after accounting for enriched pathways. Table columns from left to right are: (1) chromosomal locus; (2) region
most likely containing the risk-conferring variant(s), in Megabases (Mb); (3) posterior probability that one or more SNPs in the
region are included in the model under the null hypothesis, and (4) under the alternative hypothesis that two pathways are
enriched; (5) posterior probability that two or more SNPs are included under the null, and (6) under the alternative; (7)
established genes in Crohn’s disease pathogenesis, or most credible genes of interest, corresponding to the locus; (8) refSNP
identifier of SNP in critical region with the largest PIP; (9) frequency of minor allele for that SNP in cases, and (10) in controls.
The “critical region” at each locus is estimated by inspecting single-SNP BFs [59], and bounding the region by areas of high
recombination rate, inferred using data from Phase I, release 16a of the HapMap study [85], and visualized in the UCSC Genome
Browser [86]. All SNP information and genomic positions are based on human genome assembly 17 (NCBI build 35).
tokine signaling is enriched, 17,261 out of 17,668 segments
across the genome (97.7%) have P1 ≤ 0.1.
Points in the top-right corner of Fig. 1A correspond to
regions with strong evidence for association even without
the benefit of feedback from pathway enrichment. Genes
IL23R, PTGER4, ZNF365, NKX2-3 and ATG16L1 are not
involved in cytokine signaling, nor are any nearby genes,
so the PIPs of SNPs near these genes are unaffected by
the hypothesis that cytokine signaling is enriched. NOD2
(also known as CARD15) and PTPN2 are cytokine signaling
genes, so these associations contribute to the evidence for
enrichment of this pathway, but because they already show
strong support for association without enrichment (P1 is
close to 1 under the null hypothesis), these associations
are not greatly affected by enrichment. Reassuringly, these
results recapitulate the strongest associations reported in
the original study (Table 3 in [51]) with trend p-values less
than 4×10−8, or those with additive BFs greater than 105.4.
These results have also been replicated in a follow-up study
[62], and have been confirmed in meta-analyses with large
combined sample sizes [6, 7]. Two additional regions at 3p21
and 5q33 are reported as associations in the original study
[51], although with trend-test p-values exceeding 5× 10−8.
These Crohn’s disease associations are replicated elsewhere
[6, 7, 62], but show only modest evidence for association in
our analysis; these regions are not annotated to the cytokine
signaling pathway, and the largest P1 for segments at these
regions are 0.19 and 0.21, respectively.
Points near the top-left corner of Fig. 1A correspond to
regions of the genome that show strong support for associ-
ation only after accounting for enrichment of cytokine sig-
naling. Three additional regions stand out: the MHC class
II region, previously identified as a region showing mod-
erate evidence of association [51]; the IBD5 locus at 5q31,
which contains several candidate genes; and a region at po-
sition 17q21 near gene STAT3. Other genome-wide studies
and meta-analyses independently support Crohn’s disease
associations at these loci [6, 7, 87–91]. (See Supplementary
Results for further details on these loci.) In addition, two
loci at 16q24 and 10q22 near genes IRF8 and CAMK2G show
moderate support for association under the enrichment hy-
pothesis; P1 is 0.49 and 0.46, respectively. Neither of these
loci have been identified as being significant associations in
other Crohn’s disease studies. However, the association at
locus 16q24, 84.45–84.6 Mb near IRF8 is potentially inter-
esting, as it has previously been identified in genome-wide
studies of two other autoimmune diseases, multiple sclerosis
[92] and systemic sclerosis [93]. This gene belongs to a fam-
ily of transcription factors that regulate responses to type
I interferons (IFN-α and IFN-β), and these interferons are
known play critical roles in modulating inflammatory and
immune responses to pathogens [72].
Next we investigate whether allowing for two enriched
pathways reveals any further associations. (See Methods
for how P1 is computed by averaging over different models
with two enriched pathways.) Figure 1B shows that allow-
ing for enrichment of two pathways does not yield com-
pelling support for genetic associations beyond those re-
vealed by enrichment of cytokine signaling. However, the
segment with the greatest increase in P1, from 0.04 to 0.53,
is at 158.4–159.1 Mb on chromosome 5, near gene IL12B.
This locus was reported as a Crohn’s disease association in
[6], and was later confirmed in [7]. IL12B is also associated
with other autoimmune diseases, including ulcerative coli-
tis [94, 95] and psoriasis [96]. Note that all pathways listed
in Table 2 except cytokine signaling implicate IL12B, so the
association signal at this locus presumably contributes to
evidence for enrichment of these pathways.
Table 3 summarizes the Crohn’s disease associations
that are strongly supported by our analysis. Of the 10 re-
gions listed in this table, 3 are revealed only after prior-
itizing SNPs in enriched pathways. Each row in the ta-
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ble shows the SNP within the critical region that has the
largest PIP. In most cases, since only a portion of all com-
monly occurring SNPs are included in the study, this SNP is
most likely in linkage disequilibrium with the causal variant
rather than being causal itself. We also show in this table,
for each selected region, evidence for multiple independent
risk factors, indicated by P2, the posterior probability that
at least two SNPs in the region are independently asso-
ciated with Crohn’s disease. Our calculations suggest the
strong possibility of multiple independent risk factors at
the NOD2 locus, with P2 = 0.77, a prediction that coin-
cides with a previous study [97].
The large number of points approaching the middle of
the y-axis in Fig. 1A suggests that many other gene variants
involved in cytokine signaling may contribute to Crohn’s
disease risk. In fact, the estimates θ¯0 = −4.11 and θ¯ = 1.96
given in Table 1 imply that roughly 1 out of every 140 SNPs
in the pathway are expected to be independent associations,
for a total of about 47 independent risk factors for Crohn’s
disease hidden among “cytokine signaling in immune sys-
tem” genes. Our analysis has only identified a few of these
genes, which suggests that many more associations in this
pathway remain to be discovered. This prediction coincides
to some extent with a recent meta-analysis of Crohn’s dis-
ease association studies [7], as an additional 7 cytokine sig-
naling genes—IL1R1, IP6K2, JAK2, IL2RA, TYK2, MAPK1
andMAP3K71P1—overlap with the susceptibility loci iden-
tified in this meta-analysis.
Sensitivity of pathway ranking to prior distribution of odds
ratios
Our approach requires specification of a prior distribution
for the odds ratios (see Methods). We assume a prior in
which the log-odds ratios (i.e. the coefficients βj in the ad-
ditive model of disease risk) are normally distributed with
mean zero and standard deviation σa = 0.1. This choice is
based on odds ratios reported in published genome-wide as-
sociation studies (see Methods). One concern is that slightly
smaller or slightly larger settings of σa could also be jus-
tified, and these choices could produce different results.
Associations are unlikely to accumulate at a greater rate
in pathways that are not related to the disease, even as-
sociations with small effects on disease risk, so we predict
that the ranking of pathway enrichments is largely robust
to the choice of σa. Here we verify this claim. We assess
the sensitivity of our results to σa by recomputing the BFs
for all candidate pathways with prior choices that favor
slightly smaller (σa = 0.06, 0.08) and slightly larger coeffi-
cients (σa = 0.15, 0.2).
Fig. 2 shows that smaller settings of σa yield substan-
tially more support for enrichment of disease-related path-
ways, as expected. But the pathways with the largest BFs
are IL-23, IL-12 and cytokine signaling regardless of the
choice of σa. In the Supplementary Results, we show that
the BFs for most of the other 3158 candidate pathways do
not change substantially at different settings of σa. In sum-
mary, we conclude that the pathway-level findings in this
Crohn’s disease study are largely robust to priors that are
not substantially different from σa = 0.1.
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Fig. 2. The top four BFs for each setting of σa. In
each case, the three largest BFs correspond, in order, to
cytokine signaling in immune system, IL23-mediated
signaling events, and IL12-mediated signaling events
(these are also the top three pathways in Table 1). The
pathway with the fourth-largest BF differs across settings
of σa.
Discussion
Pathway analysis for genome-wide association studies has
been as advertised as a way to overcome some of the lim-
itations of conventional approaches to identifying genetic
factors underlying polygenic traits. Motivated by the obser-
vation that it is easier, in principle, to identify associations
within an enriched pathway, we developed a model-based
approach for simultaneously estimating enrichment and pri-
oritizing variants in enriched pathways. We investigated the
merits and limitations of this approach in a GWAS for
Crohn’s disease. In this case study, we interrogated over
3,000 candidate pathways from several pathway databases,
and confirmed the importance of the IL-12 and IL-23 path-
ways in Crohn’s disease pathogenesis and, more broadly,
the role of cytokines that mediate immune responses. By
prioritizing variants within the enriched pathways identi-
fied in our analysis, we established strong support for dis-
ease susceptibility loci beyond what are revealed by a con-
ventional analysis that ignores this pathway information.
This suggests that applying our methods to larger samples
may reveal genetic loci that have not yet been identified
as risk factors for Crohn’s disease and other common dis-
eases. Moreover, leveraging knowledge about variants that
modulate expression of genes (eQTLs) may also lead to
stronger evidence for pathway enrichments, and for associ-
ations within these pathways.
Our approach to modeling enrichment was built on
large-scale sparse regression methods that have been ap-
plied to other problems in statistics and genetics. The key
idea behind our approach was to introduce a parameter, θ,
that quantifies enrichment—precisely, the increase in the
probability that a SNP assigned to a pathway is included
in a polygenic model of the phenotype. Given the generality
of this approach, our method could be useful for problems
outside genetic association studies. One caveat is that some
of the approximations we used—approximations which help
scale the computations to hundreds of thousands of SNPs
and thousands of candidate pathways (see Supplementary
Methods)—may not be appropriate in some settings.
One attractive feature of our approach, which we illus-
trated in the Crohn’s disease case study, is that it can be
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used to assess how well the data support enrichment of dif-
ferent combinations of multiple pathways. Examining com-
binations of pathways for enrichment may highlight inter-
esting pathways that would not otherwise be highly ranked.
An example of this was the “IL-12 and Stat4 dependent
signaling” pathway, which showed little support for enrich-
ment on its own (BF = 18), but became more interesting
when considered jointly for enrichment with cytokine sig-
naling genes (BF = 2.4× 108).
In contrast to many pathway analysis methods, we mod-
eled pathway enrichment at the level of variants, rather
than genes. While there are arguments for both approaches,
a feature of the variant-based approach is that, when there
are multiple independent association signals near a gene,
all these signals contribute to the evidence for enrichment
of pathways containing this gene.
The Crohn’s disease study was aimed at identifying
common variants associated with disease, but there is grow-
ing interest in using exome and whole-genome sequencing
to investigate the contribution of rare variation to complex
diseases and traits [98–100]. The computational complexity
of our method grows linearly with the number of SNPs, so it
should scale well to the large amount of data generated by
high-throughput sequencing. Since detecting associations
with individual rare variants is a hard problem [101, 102],
pathway-based analysis approaches such as ours that ag-
gregate association signals across sets of genes may play an
important role in analysis of these studies.
Currently, a drawback to our approach is that the prior
variance of additive effects on disease risk must be chosen
beforehand. We based our choice on the distribution of odds
ratios reported in published genome-wide association stud-
ies, and checked that the rankings of enriched pathways
were robust to different prior choices. Ideally, we would es-
timate this parameter from the data instead, but, as we
discussed in Methods, we found that this did not work well
for the Crohn’s disease data. In our estimation, the root
of the problem is that the log-odds ratios are not normally
distributed (currently, we assume that non-zero effects fol-
low a normal distribution). One possible solution would be
to use a more flexible distribution for the effect sizes, such
as a mixture of two or more normals, but we have not in-
vestigated this direction as it raises a number of questions
regarding modeling and computation. Despite this issue,
we believe that we have presented a useful framework for
identifying enriched pathways and genetic associations un-
derlying these pathways.
Method
Samples
Our analysis is based on genome-wide marker data from a
case-control study with 1748 subjects affected by Crohn’s
disease, and 2938 control subjects. The controls come from
two groups: 1480 individuals from the 1958 Birth Cohort,
and 1458 individuals from the UK Blood Services cohort.
All subjects are from Great Britain, and of self-described
European descent. Genetic associations from this study
were first reported in [51].
All study subjects were genotyped for ∼500, 000 SNPs
using a commercial version of the Affymetrix GeneChip
500K platform. We apply quality control filters as described
in [51], and remove SNPs that exhibit no variation in the
sample. We discarded two additional SNPs, rs1914328 on
chromosome 8 and rs6601764 on chromosome 10, because
they show some evidence for association (single-SNP BFs
[59] of 103.5 and 103.6, respectively), but we cannot rule
out the possibility of genotyping errors as these associa-
tions are not supported by nearby SNPs (none of the nearby
SNPs have single-SNP BFs greater than 40). After remov-
ing these two SNPs, we end up with 442,001 SNPs on au-
tosomal chromosomes. We estimate missing genotypes at
these SNPs using the mean posterior minor allele count
from BIMBAM [59, 103], with SNP data from Phase II of
the International HapMap Consortium project [104]. To be
consistent with the original analysis, refSNP identifiers and
locations of SNPs are based on human genome reference
assembly 17 (NCBI build 35).
Population stratification
Analysis of pathways should, in principle, be robust to
population stratification because spurious associations that
arise from population structure are unlikely to accumulate
at a greater rate in the pathway—recall, we define the en-
richment parameter as the increase in proportion of vari-
ants associated with disease risk relative to the proportion
genome-wide. However, population stratification could still
produce individual false positive associations, either inside
or outside enriched pathways, so in general one should ac-
count for this in the analysis [3, 4, 105–107]. For the Crohn’s
disease study, the original report [51] and subsequent anal-
yses [6, 108] affirm that cryptic population structure does
not have a substantive impact on the analysis. Thus we
do not attempt to correct for population structure in our
analysis.
Pathways, and assignment of SNPs to pathways
We aim for a comprehensive evaluation of pathways ac-
cessible on the Web in standard, computer-readable for-
mats [49, 50, 116]. Since the results hinge on the quality
of the pathways used in our analysis, we restrict the anal-
ysis to curated, peer-reviewed pathways based on experi-
mental evidence, and pathways inferred via gene homology.
We draw candidate pathways from the collections listed in
Table 4 (see Supplementary Methods for details). KEGG
and HumanCyc are primarily databases of metabolic path-
ways, and are unlikely to be relevant to Crohn’s disease,
but we include them for completeness.
Since we combine pathways from different sources, we
encounter pathways with inconsistent definitions [117, 118].
There is no single explanation for the lack of consensus
in pathway definitions, and we have no reason to prefer
one definition over another, so we include multiple ver-
sions of a pathway in our analysis. Many of the pathways
in these databases are arranged hierarchically; we incor-
porate all elements of the hierarchy into our analysis. We
treat each candidate pathway as a set of genes, ignoring
details such as molecules involved in biochemical reactions,
and cellular locations of these reactions. From 3788 to-
tal pathways (Table 4), we obtain 3158 unique gene sets.
With these pathways we achieve ∼39% gene coverage (see
Supplementary Results).
Based on findings that the majority of variants modu-
lating gene expression lie within 100 kb of the gene’s tran-
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Table 4. Overview of pathways used in the analysis
database refs. download location #pathways
BioCarta
www.openbioinfor-
298matics.org/gengen
Cancer Cell Map Pathway Commons 10
HumanCyc 109, 110
NCBI BioSystems 54
Pathway Commons 224
Kyoto Encyclopedia of Genes
and Genomes (KEGG)
111 NCBI BioSystems 399
NCI Nature Pathway
64
NCBI BioSystems 186
Interaction Database (PID) Pathway Commons 179
PANTHER 112, 113 www.pantherdb.org 128
Reactome 63
NCBI BioSystems 1093
Pathway Commons 1070
WikiPathways 114, 115 NCBI BioSystems 147
From these 3788 pathways, we obtain 3158 unique gene sets.
scribed region [119–121], we assign a SNP to a gene if it is
within 100 kb of the transcribed region. Others have opted
for a 20 kb window [52, 55] based on findings that cis-acting
expression QTLs are rarely more than 20 kb from the gene
[48]. We prefer a more inclusive mapping of SNPs to genes,
since the benefit of including potentially relevant SNPs in a
pathway when the association signal is sparse seems likely
to outweigh the cost of including a larger number of irrele-
vant markers.
Statistical analysis
The Bayesian variable selection approach to simultaneous
interrogation of SNPs involves fitting the multi-marker dis-
ease model to the data using different combinations of
SNPs. Fitting all markers simultaneously weeds out mul-
tiple associations at markers that are in linkage disequi-
librium with one another, leaving only one marker for each
independent association—an association that signals a vari-
ant contributing to disease risk independently of other risk-
conferring variants.
Likelihood
The likelihood specifies the probability of observing the
phenotype observations y given the genotypes X, the in-
tercept β0, and the regression coefficients β = (β1, . . . , βp).
From the additive model for the log-odds of disease (eq. 1),
pi = ψ
(
β0 +
∑p
j=1 xijβj
)
is the probability that yi = 1, in
which ψ(x) = 1/(1+e−x) is the sigmoid function. Assuming
independence of the observations yi, the likelihood is
p(y |X, β0, β) =
n∏
i=1
pyii (1− pi)1−yi . (4)
Priors
Next we specify prior distributions for the genome-wide log-
odds θ0, the enrichment parameter θ, the intercept β0, and
the coefficients βj of SNPs included in the multi-marker
model of disease risk.
Since inferences strongly depend on θ0, and since θ0 is
unknown and will be different for each setting, we estimate
this parameter from the data rather than fix it a priori.
Following [36, 37], we assign a uniform prior to θ0. We re-
strict θ0 to [−6,−2], so as few as 0 and as many as ∼4400
SNPs are expected to be included a priori.
We place a uniform prior on θ, restricted to [0, 3]. This
prior permits a wide range of enrichments because, in our
view, enrichments greater than a thousand-fold are unlikely
to occur. Note that we do not allow negative enrichments;
that is, we do not consider pathways that are underrep-
resented for associations with the phenotype. Negative en-
richments could potentially be useful in other scenarios, but
for most genome-wide association studies where there are
generally few significant associations to begin with, nega-
tive pathway enrichments are difficult to find and are un-
likely to have a useful interpretation.
For the prior on the non-zero coefficients βj , we follow a
standard practice that assumes they are i.i.d. normal with
zero mean and standard deviation σa [122, 123]. Ordinarily,
to combat sensitivity of the results to the choice of σa, we
would place a prior on σa and integrate over this parameter
to let the data drive selection of σa. This approach is taken
in [36, 37]. But in our case, we find that the heterogene-
ity of the odds ratios in Crohn’s disease presents a prob-
lem: although we expect most odds ratios for a common
disease—and specifically odds ratios in a pathway relevant
to disease pathogenesis—to be close to 1, the odds ratios
corresponding to the strongest Crohn’s disease associations
drive estimates of σa toward larger values, and a normal
distribution that puts too little weight on modest odds ra-
tios. One possible strategy would be to redo the analysis
after removing associated regions with the largest odds ra-
tios, but this is an unattractive solution because SNPs with
large odds ratios would not contribute to the evidence for
enrichment. Instead, we fix σa, grounding the choice on typ-
ical odds ratios reported in published genome-wide associ-
ation studies, and we assess the robustness of our findings
to this choice. (There is the potential for more principled
solutions; see Discussion.) Our choice is σa = 0.1, which
favours odds ratios close to 1 (95% of the odds ratios lie
between 0.82 and 1.22 a priori), while being large enough
to capture a significant fraction of the odds ratios for com-
mon alleles reported in genome-wide association studies of
complex disease traits. According to a recent review [15],
approximately 40% of estimated odds ratios are between 1.1
and 1.2, and an additional 10% of odds ratios are smaller
than 1.1. This prior also closely corresponds to a survey of
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odds ratios reported in genetic association studies of com-
mon diseases [124]. Since there may be justification for a
slightly smaller or slightly larger σa, we also try different
values for σa, and examine how these choices affect the
ranking of enriched pathways (see Results).
To complete the probability model, we assign an im-
proper uniform prior to the intercept, β0. In general, one
must be careful with use of improper priors in Bayesian
variable selection because they can result in improper pos-
teriors. A sufficient condition for a proper posterior, and a
well-defined BF, with logistic regression (eq. 1) is that the
maximum likelihood estimator of β conditioned on which
variables are included in the model, and on the other model
parameters, is unique and finite [125]. Unfortunately, this
condition is difficult to check exhaustively. But we can at
least guarantee that the posterior is proper under the varia-
tional approximation (see Supplementary Methods) so long
as the coordinate ascent steps converge to a unique solu-
tion.
Bayes factors and posterior odds
Ideally, we would assess evidence for an enrichment model
by computing the posterior probability for that model. But
computing these posterior probabilities is impractical for
several reasons, one being that it would involve compu-
tations for a large number of combinations of pathways.
Instead, we compute a Bayes factor (3) for each candidate
pathway, or combination of pathways, then we weigh the
Bayes factor against the prior odds to obtain the posterior
odds for the enrichment model:
(posterior odds)
p(θ > 0 |X, y, a)
p(θ = 0 |X, y, a) =
(Bayes factor)
p(y |X, a, θ > 0)
p(y |X, a, θ = 0) ×
(prior odds)
p(θ > 0)
p(θ = 0)
. (5)
In our pathway enrichment results (Tables 1 and 2), we
report BFs rather than posterior odds. Although our results
would be more straightforward to interpret had we provided
posterior odds instead of BFs, posterior odds are easily ob-
tained from BFs, and reporting BFs offers the reader flexi-
bility to judge the evidence based on his or her own prior. In
the results, we illustrate how to gauge support for each en-
richment hypothesis by weighing against a “conservative”
prior. However, the reader may have reason to choose a
different prior, such as one that favours certain pathways
above others.
To allow for uncertainty in θ0 and θ when evaluating
the BFs, the likelihood under the enrichment hypothesis
(θ > 0) and the likelihood under the null (θ = 0) are each
expressed as an average over possible assignments to θ0 and
θ:
BF(a) =
∫∫
p(y |X, a, θ0, θ) p(θ0) p(θ) dθ dθ0∫
p(y |X, a, θ0, θ = 0) p(θ0) dθ0 . (6)
Each instance of p(y |X, a, θ0, θ) in (6) expands as an av-
erage over possible assignments to the intercept β0 and re-
gression coefficients β:
p(y |X, a, θ0, θ) =
∫∫
p(y |X, β0, β) p(β0)
×
p∏
j=1
p(βj | aj , θ0, θ) dβ0 dβ. (7)
Factor p(βj | aj , θ0, θ) = pijN(0, σ2a)+(1−pij) δ0 is the “spike
and slab” prior [122, 123], in which pij = p(βj 6= 0) is
determined according to (2). Here, δ0 denotes the delta
mass, or “spike”, at zero, N(µ, σ2) is the normal density
with mean µ and variance σ2, p(β0) is the (improper) uni-
form prior, and p(y |X, β0, β) is the logistic regression like-
lihood (4). Computation of Bayes factors is described in
Supplementary Methods.
Posterior inclusion probabilities and other statistics
Here we define PIPs and other posterior quantities used in
our analysis for the case when a pathway, or combination
of pathways, is enriched. Posterior statistics under the null
hypothesis are obtained by setting θ = 0.
Like the BFs, the PIPs are obtained by averaging over
θ0 and θ. Taking D = {X, y, a} as shorthand for all the
data, we have
PIP(j) ≡ p(βj 6= 0 |D)
=
∫∫
p(βj 6= 0 |D , θ0, θ) p(θ0, θ |D) dθ0 dθ. (8)
To identify regions of the genome associated with dis-
ease risk, we calculate, for each region, the posterior prob-
ability that at least one SNP in the region is included in
the multi-marker disease model (see Results for an expla-
nation). Let S = n represent the event that exactly n SNPs
in a given region are included in the multi-marker disease
model, so that P1 = p(S ≥ 1 |D). These posterior statistics
are easily calculated from the PIPs using the variational
approximation (see Supplementary Methods).
Since no pair of pathways stands out in Table 2 as hav-
ing greater support than any other pair, we compute the
posterior statistics P1 by averaging over the different mod-
els with two enriched pathways, including models with BFs
too small to be included in the table, weighting these mod-
els by their BFs. Implicitly, this assumes that all models
with two enriched pathways are equally plausible a pri-
ori. The ability to average across models in this way is
an advantage of adopting the Bayesian approach to model
comparison, because it allows us to assess genetic associ-
ations in light of the enrichment evidence without having
to choose a single pair of pathways. Suppose we have m
enrichment models a(1), . . . , a(m) with corresponding Bayes
factors BF(a(1)), . . . ,BF(a(m)), then P1 for a given region
is
P1 =
∑m
i=1 p(S ≥ 1 |D , a(i)) BF(a(i))∑m
i=1 BF(a
(i))
. (9)
Further details about computation of posterior statistics
are given in Supplementary Methods.
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Appendix A: Supplementary Methods
Pathways
We retrieve most of the pathways from the Pathway
Commons [66] and NCBI BioSystems [65] repositories.
From the Pathway Commons website, we download the
October 26, 2011 version of Gene Matrix Transposed
(.gmt) file for homo sapiens. To retrieve BioSystems path-
ways, we first get the pathway names and IDs by searching
for ‘‘homo sapiens’’[organism], then save the search re-
sult as a CSV file. Next, we download the November 15,
2011 version of the biosystems gene file from the NCBI
FTP site, which provides associations between genes and
pathways. These two repositories include pathways from
the same databases, but due to differences in versions of
the databases and data processing procedure, there are
discrepancies among pathways. At present, BioSystems ig-
nores nesting relationships between pathways in the PID.
This can lead to large discrepancies in pathway gene sets,
notably in the IL23-mediated signaling pathway.1 Since we
cannot fully account for all discrepancies in the BioSystems
and Pathway Commons gene sets, whenever there is dis-
agreement we include both gene sets, and assess evidence
for enrichment of these gene sets separately in our analysis.
We download a version of the BioCarta database at
www.openbioinformatics/gengen. We use this version of
the BioCarta data because it was used in an previous path-
way analysis of Crohn’s disease [55]. We download version
3.01 of the PANTHER “sequence association” file from
their FTP site. From the sequence association file, we re-
tain lines containing ENSG* accession numbers (correspond-
ing to human genes) and remove entries that do not map
to Entrez gene IDs.
The numbers given in Table 4 are tabulated after dis-
carding 213 pathways with less than two genes that map
to the reference genome, and after removing 44 PID path-
ways from Pathway Commons that contain over 500 genes
because their definitions include a large number of nested
pathways. We include all groups of pathways except for two
unusually large gene sets from the KEGG database that
are unions of related pathways, “metabolic pathways” and
“pathways in cancer.”
Computation
The main difficulty in computing the Bayes factor (eq. 3)
is the combinatorially large number of ways we can include
1 Personal communication with Lewis Geer and Emek Demir.
SNPs in the additive model of disease risk. In previous
work [36], we described an approximation that yields an
efficient procedure for computing the likelihood and PIPs.
(Actually, this approximation was derived for the specific
case when all variables have the same prior inclusion proba-
bility, or when θ = 0, but it is straightforward to extend this
approximation to the more general case with θ > 0.) Once
we have a recipe for efficiently computing p(y |X, a, θ0, θ),
we are left with the task of computing a one-dimensional
integral in the denominator of (6), and a double integral in
the numerator. Each of these integrals is then approximated
using simple numerical integration techniques.
The basic idea behind this approximation is to formu-
late a lower bound to the likelihood,
p(y |X, a, θ0, θ) ≥ eF (D,θ0,θ,φ), (10)
then to adjust the free parameters, denoted by φ, so that
this bound is as tight as possible. (The exact form of
F (D , θ0, θ, φ) is derived in [36], and is given below.) This
lower bound is formulated by introducing a probability dis-
tribution q(β;φ) that approximates the posterior of β given
θ0 and θ so that maximizing the lower bound corresponds
to finding the approximating distribution that best matches
the posterior. More precisely, it amounts to searching for
the free parameters φ that minimize the Kullback-Leibler
divergence between q(β;φ) and the posterior of β given θ0
and θ [126]. The trick to making this approach tractable
lies in forcing q(β;φ) to observe a simple conditional in-
dependence property, as originally suggested by [40]: each
regression coefficient βj is independent of the other coeffi-
cients a posteriori given θ0 and θ. In other words, we restrict
this distribution to be of the form
q(β;φ) =
∏p
j=1 q(βj ;φj), (11)
where φj is the set of free parameters corresponding to the
jth factor.
For most SNPs, this conditional independence assump-
tion is appropriate—most SNPs are unlinked because they
are on separate chromosomes, or they are weakly linked
because of recombination. In this case, the fully-factorized
approximation q(β;φ) will closely recover the correct pos-
terior distribution of the additive effects for these SNPs.
But the conditional independence assumption is violated
for SNPs in linkage disequilibrium. In that case, we do
not expect to obtain accurate posterior statistics and, in
practice, we find that the lower bound (10) can be a poor
substitute to the correct likelihood. However, we are inter-
ested in accurate computation of BFs, not individual like-
lihoods, so what matters is whether eF (D,θ0,θ,φ) correctly
captures the shape of the likelihood, or how the likelihood
p(y |X, a, θ0, θ) changes as a function of θ0 and θ; if the
lower bound undershoots the exact likelihood by a constant
factor across different settings of θ0 and θ, this constant fac-
tor will cancel out in the BF. In [36], we show that the vari-
ational approximation (when the phenotype is a quantita-
tive trait) can closely reproduce the shape of the likelihood,
and can give accurate estimates of some posterior quanti-
ties, even when the conditional independence assumptions
are not particularly appropriate. We caution, however, that
the accuracy the approximation has only been assessed em-
pirically, and we have no theoretical guarantees of its accu-
racy.
16
Carbonetto and Stephens: Integrated analysis of variants and pathways in genome-wide association studies
Computing the Bayes factor for one pathway
To start, we formulate a simple piecewise numerical approx-
imation to the integrals in (6) based on Simpson’s rule [127].
We replace each instance of the likelihood p(y |X, a, θ0, θ)
with its corresponding lower bound (10). Following the dis-
cussion above, we have
BF(a) ≈
∫∫
eF (D,θ0,θ,φ(θ0,θ)) p(θ0) p(θ) dθ dθ0∫
eF (D,θ0,θ=0,φ(θ0,θ=0)) p(θ0) dθ0
, (12)
so the numerical approximation to the BF is
BF(a) ≈ Ialt
Inull
=
∑
i
∑
j wije
F (D,θ
(i)
0 ,θ
(j),φ(θ
(i)
0 ,θ
(j))) p(θ
(i)
0 ) p(θ
(j))∑
iwie
F (D,θ
(i)
0 ,θ=0,φ(θ
(i)
0 ,θ=0)) p(θ
(i)
0 )
, (13)
where wi and wij are weights obtained by applying
Simpson’s rule. To calculate the numerical approximation
to the null likelihood, Inull, we evaluate the lower bound
at equally spaced points over the interval [−6,−2]. The
likelihood under the alternative is a double integral, so we
evaluate the lower bound at points on a regular grid over
the rectangular region θ0 ∈ [−6,−2], θ ∈ [0, 3]. In eq. 13,
the free parameters φ are expressed as a function of θ0 and
θ because we adjust them separately for each setting of
the hyperparameters (θ0, θ). (Optimizing φ involves iterat-
ing coordinate ascent steps until these steps converge to
stationary point which constitutes a locally optimal bound
to the likelihood. Full details about the procedure to solve
for φ are given in [36]. This procedure scales linearly with
the number of samples and the number of SNPs.) Adjusting
the free parameters for each setting of the hyperparameters
can be an costly endeavor for a large problem, so to reduce
the expense of computing the BF we formulate piecewise
numerical approximations to the integrals using a small
number of equally spaced points at intervals of length 0.25,
so θ
(i)
0 = −6,−5.75, . . . ,−2 and θ(j) = 0, 0.25, . . . , 3. This
coarse partitioning risks some loss of accuracy, especially if
the posterior distribution of the hyperparameters is sharply
peaked inside the subintervals, and a finer grid is certainly
possible. An adaptive method that refines the subintervals
in the piecewise approximation could have been used in-
stead [127], but we stick to this simple scheme with equally
spaced points at larger subintervals because it allows us to
compute BFs for all ∼3000 candidate pathways in a reason-
able amount of time.
The analytic expression for the lower bound to the log-
likelihood is derived in the Appendix of [36] and, for con-
venience, we reproduce it here:
F (D , θ0, θ, φ) = log σˆ0 +
y¯2
2u¯
+
n∑
i=1
logψ(ηi)
+ ηi2 (uiηi − 1) + yˆTXr − 12rTXT UˆXr
− 1
2
p∑
j=1
(XT UˆX)jjVar[βj]
+
p∑
j=1
αj
2
[
1 + log
(
s2j
σ2a
)
− s
2
j + µ
2
j
σ2a
]
−
p∑
j=1
αj log
(αj
pij
)
−
p∑
j=1
(1− αj) log
(1− αj
1− pij
)
, (14)
where the sigmoid function ψ(x) is defined above, and the
prior inclusion probability pij for each SNP is given by (2).
For this expression we introduce the following definitions:
αj is the PIP for SNP j with respect to the approximating
distribution q(β;φ), µj and s
2
j are the approximate mean
and variance of coefficient βj conditioned on being included
in the model, Var[βj] = αj(µ
2
j+s
2
j)−(αjµj)2 is the variance
of βj with respect to the approximating distribution, r is
a column vector with entries rj = αjµj , σˆ0 = 1/
√
u¯ is
the standard deviation of the intercept β0 given β, βˆ0 =
y¯/u¯ is the posterior mode of the intercept β0 when β =
0, (XT UˆX)jj is the jth diagonal entry of matrix product
XT UˆX, and we define u¯ =
∑n
i=1 ui, y¯ =
∑n
i=1(yi − 12 ),
yˆ = y− 12 − βˆ0u, Uˆ = U −uuT/u¯, u is a column vector with
entries ui = (ψ(ηi)− 12 )/ηi, and U is the n×n matrix with
diagonal entries ui.
In [36], to derive this analytic expression for the lower
bound we made an additional approximation to the non-
linear factors appearing in the logistic regression likeli-
hood p(y |X, β0, β), following [128, 129]. This approxima-
tion introduces an additional set of free parameters, η =
(η1, . . . , ηn), so implicitly the lower bound (14) is a func-
tion of η as well. Like φ, we adjust η separately for each
hyperparameter setting (θ0, θ). The procedure to solve for
η is given in [36].
Since the coordinate ascent updates used to solve for
φ and η are only guaranteed to converge to a local maxi-
mum of the lower bound, the choice of starting point can
affect the tightness of the lower bound, and the quality of
the approximation. As we explain in [36], this issue can
be addressed somewhat by using a common initialization
(φ(init), η(init)) for the coordinate ascent updates across all
grid points (θ
(i)
0 , θ
(j)), in which this initialization is selected
by first running the coordinate ascent procedure separately
for each grid point, with random initializations for φ and η,
then assigning (φ(init), η(init)) to the solution from the hy-
perparameter setting with the largest marginal likelihood
estimate. In practice, when we follow this procedure we find
that final estimates of BFs and posterior statistics vary only
slightly when the analysis is re-run with different random
initializations. However, we cannot guarantee the possibil-
ity that a new random starting point leads to the discovery
of a much better approximation.
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Computing the posterior inclusion probabilities and other pos-
terior statistics
In this section, we describe computation of PIPs and other
posterior statistics when a pathway, or a combination of
pathways, is enriched. Computation of these quantities un-
der the null hypothesis proceeds in a similar manner by
setting θ = 0.
Following the procedure for computing the BFs, we for-
mulate a piecewise numerical approximation to the integral
in (8), substituting each PIP conditioned on θ0 and θ with
the corresponding variational approximation, αk(θ0, θ) ≈
p(βk 6= 0 |D , θ0, θ). This yields the following approximate
PIP:
PIP(k) ≈∑i∑j w˜ij αk(θ(i)0 , θ(j)), (15)
where we define
w˜ij ∝ wij eF (D,θ
(i)
0 ,θ
(j),φ(θ
(i)
0 ,θ
(j))) p(θ
(i)
0 ) p(θ
(j)),
such that
∑
i
∑
j w˜ij = 1. Other posterior quantities are
computed by averaging over θ0 and θ in a similar way. For
example, the posterior mean enrichment estimate is
θ¯ = E[θ |D]
=
∫∫
θ p(θ0, θ |D) dθ0 dθ ≈
∑
i
∑
j w˜ij θ
(j). (16)
To compute credible intervals for θ, we add up the nor-
malized weights w˜ij over successively wider intervals of θ,
beginning at the posterior mean θ¯, until the sum of the nor-
malized weights w˜ij reaches 0.95. As a result, the credible
intervals are at the same resolution as the grid points used
for the numerical approximation.
The estimate of the posterior probability that at least
one SNPs in a given segment of the genome is included in
the additive model of disease risk is
P1 ≈
∑
i
∑
j w˜ij p(S ≥ 1 |D , θ(i)0 , θ(j))
=
∑
i
∑
j w˜ij
[
1− p(S = 0 |D , θ(i)0 , θ(j))
]
. (17)
where S = n represents the event that n SNPs in the seg-
ment are included in the model. Assume without loss of
generality that SNPs in the segment are labeled 1 through
m. Since the regression coefficients are independent under
the fully-factorized approximating distribution given θ0 and
θ, we have
p(S = 0 |D , θ0, θ) = p(β1 = 0 ∧ · · · ∧ βm = 0 |D , θ0, θ)
≈∏mk=1(1 − αk(θ0, θ)), (18)
so our final estimate of this posterior statistic is
P1 ≈
∑
i
∑
j w˜ij
[
1−∏mk=1(1− αk(θ(i)0 , θ(j)))]. (19)
To compute P2 = p(S ≥ 2 |D) for a given segment, we
observe that p(S ≥ 2) = 1−p(S = 1)−p(S = 0), and under
the fully-factorized variational approximation, we have that
p(S = 1 |D , θ0, θ)
= p(β1 6= 0 ∧ β2 = 0 ∧ · · · ∧ βm = 0 |D , θ0, θ) + · · ·
+ p(β1 = 0 ∧ · · · ∧ βm−1 = 0 ∧ βm 6= 0 |D , θ0, θ)
≈
[
m∏
k=1
(1− αk)
]
×
[
m∑
k=1
αk
1− αk
]
. (20)
Scaling computation to many pathways
Numerical integration together with the variational approx-
imation makes it practical to compute BF(a) for one path-
way, but computing BFs for thousands of pathways is still
a costly undertaking. We introduce a simplifying assump-
tion which, we show, yields substantial savings in compu-
tation. We make the assumption that SNPs outside the en-
riched pathway are unaffected by the pathway enrichment
a posteriori. Formally, this means that p(βA¯ |D , θ0, θ) =
p(βA¯ |D , θ0, θ = 0), where A is the set of SNPs assigned to
the enriched pathway, and A¯ is the remaining set of SNPs.
In other words, the posterior distribution of the regression
coefficients for SNPs outside the enriched pathway remains
the same under the null and enrichment models. With this
assumption, the posterior distribution of β given the hy-
perparameters θ0 and θ becomes
p(β |D , θ0, θ) = p(βA |D , θ0, θ, βA¯)
× p(βA¯ |D , θ0, θ = 0). (21)
This assumption amounts to conditioning on the additive
effects of SNPs outside the enriched pathway.
It is of course possible that SNPs contributing evidence
for pathway enrichment are correlated with SNPs outside
the pathway, invalidating this assumption. But because we
assign SNPs to pathways in contiguous blocks (we anno-
tate all SNPs within 100 kb of a gene in the pathway; see
Methods), and because the way we assign SNPs to genes
is not precise (many SNPs assigned to a gene are probably
not relevant to the gene), errors as a result of this assump-
tion are expected to be minor compared to the imprecision
in the SNP-pathway assignments. On the other hand, if we
were to assign SNPs to pathways more precisely (e.g. a SNP
known to modulate expression of a gene in the pathway),
then this assumption would not be appropriate.
Next, we show how this assumption allows us to reuse
computations. This assumption implies that, for any SNP
j that is not assigned to the enriched pathway, q(βj ;φj)
remains the same under the null and enrichment models;
that is, for any j /∈ A, φj = φ∗j , in which q(β;φ) approxi-
mates the posterior distribution of β given θ0, and θ = 0,
and q(β;φ∗) approximates the posterior distribution of β
given θ0 and θ > 0. From this result, the lower bound can
be written as
F (D , θ0, θ, φ
∗) = F (D , θ0, θ = 0, φ)
+ F ({XA, yˆA, aA = 1}, θ0, θ, φ∗A)
− F ({XA, yˆA, aA = 1}, θ0, θ = 0, φ∗A), (22)
where XA is the matrix of genotypes for SNPs assigned
to the enriched pathway, φA is the set of free parameters
corresponding to SNPs j ∈ A, aA is the set of pathway
annotations restricted to SNPs j ∈ A (so aA is a vector of
ones), and yˆA = y − UˆXA¯rA¯ is the vector of binary labels
“corrected” for SNPs outside the pathway, where XA¯ is the
genotype matrix for SNPs j /∈ A, and rA¯ is the vector r with
entries rj = αjµj restricted to SNPs j /∈ A. Note that (22)
is valid only if η is held constant.
Identity (22) suggests a way to reuse our computations:
once we have solved for φ(θ0, θ = 0), the free parameters
φ that (locally) maximize the lower bound under the null
hypothesis (θ = 0) for a given θ0, to solve for φ(θ0, θ) for
any θ > 0, we only need to adjust the free parameters φj
corresponding to SNPs j in the enriched pathway. Crucially,
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Fig.A.1. Panel A: histogram of gene set sizes for pathways used in the analysis. Panel B: histogram of the number of
pathways assigned to genes. Panel C: histogram of the number of SNPs assigned to genes. These counts include
multiple versions of pathways from Pathway Commons and BioSystems.
η must be held constant in (22), so for any θ > 0, we set
η(θ0, θ), the free parameters η adjusted for setting (θ0, θ)
of the hyperparameters, to η(θ0, θ = 0).
Appendix B: Supplementary Results
Pathway database statistics
We observe a wide range in the number of genes assigned to
each pathway (Fig. A.1A). Some of the larger gene sets are
groups of related pathways in the Reactome and PID hier-
archies. Out of ∼23,000 genes in the reference genome, 9054
(∼39%) are assigned to at least one pathway. The number
of pathway assignments per gene varies widely (Fig. A.1B).
Among genes assigned to at least one pathway, 95% are
within 100 kb of a SNP, and 45% of SNPs are mapped
to at least one gene in a pathway (Fig. A.1C). Figure B.1
depicts the hierarchical relationships among pathways in
Table 1.
More details on associations given enrichment of cytokine sig-
naling genes
Here we supply a few more details about regions of the
genome that show strong support for association only after
accounting for enrichment of cytokine signaling: the MHC
class II region, the IBD5 locus, and a region at 17q21 near
gene STAT3. Without pathway enrichment, the segment
with the highest P1 at 17q21 is only 0.12, but this increases
to 0.79 in the model in which cytokine signaling is enriched.
This association was first identified in a meta-analysis [6],
and was later confirmed in [7]. STAT3, the most compelling
disease-susceptibility gene at this locus, plays a key role in
Th17 cell differentiation and IL-23 signaling [76, 130, 131].
It has also been identified as a risk factor for other autoim-
mune diseases, including ulcerative colitis [94, 95].
Enrichment of cytokine signaling also yields greater
support for an association in the IBD5 region at position
5q31, increasing the probability of an included SNP from
P1 = 0.18 to P1 = 0.81. The IBD5 locus was first identified
in a genome-wide study of individuals from Quebec [89],
and this finding has since been replicated and refined by
several studies [6, 7, 90, 132]. It was identified as a modest
association for Crohn’s disease in the original report (Table
4 in [51]) with trend p-value 5.4 × 10−6 and BF = 104.54.
The IBD5 locus includes several candidate genes in a region
of extensive linkage disequilibrium. Despite this, identifica-
tion of this locus has suggested the contribution of gene
variants affecting epithelial barrier integrity in Crohn’s dis-
ease pathogenesis [10, 133].
The MHC class II region, previously identified as a re-
gion showing moderate evidence of association [51], be-
comes a stronger association when cytokine signaling is en-
riched, as P1 increases from 0.49 to 0.98. The MHC is one of
the most thoroughly studied regions of the human genome
for its contribution to regulation of the immune system.
Association of this locus (also known as IBD3) is widely
replicated for Crohn’s disease [7, 87, 88, 91], ulcerative col-
itis [134] and, not surprisingly, many other autoimmune dis-
eases [87, 135]. The extensive linkage disequilibrium across
this gene-dense region complicates identification of disease-
susceptibility variants; see [87] for a detailed examination
of specific MHC genes contributing to Crohn’s disease risk.
We also note that evidence for association of the MHC class
I genes, including TNF, is low under the null in our anal-
ysis, with P1 = 0.08, and increases to P1 = 0.52 once we
account for enrichment of cytokine signaling.
Additional results of sensitivity analysis
Under the null hypothesis, there is a clear trend in the
overall effect of the choice of σa on the distribution of asso-
ciations; we observe that the posterior mean of the genome-
wide log-odds θ0 increases as σa decreases (Fig. B.2). For
instance, the normal prior with standard deviation 0.06 cor-
responds to a posterior mean of θ¯0 = −3.4 and prior inclu-
sion probabilities of roughly 10−3.4 ≈ 0.00044 under the
null hypothesis, which is more than double the proportion
of SNPs that are independent associations (0.00018) when
σa = 0.1.
Fig. B.3 depicts the distribution of BFs for different
choices of σa. For most of the candidate pathways, the sup-
port for enrichment does not change much.
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Fig.B.2. Posterior mean of θ0 for each choice of σa. Error bars depict 95% credible intervals.
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Fig.B.3. Distribution of BFs for different settings of σa.
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